Search This Blog

Wednesday, November 18, 2026

NSA outage said to disrupt hub tied to Middle East operations

 Technology disruptions at the United States National Security Agency (NSA) hit a key Georgia facility supporting signals intelligence and cybersecurity operations for the Middle East amid the US war with Iran, CNN reported, citing four sources.

Personnel in Georgia could not use NSANet, an internal classified communications network, to communicate with colleagues in the region, though officials said key intelligence-gathering systems continued operating through backups, workarounds, and "compartmented" networks.

Officials said the outage was not a cyberattack and appeared linked to handling software updates for PHP vulnerabilities found with artificial intelligence tools, as restoration moved "slower than expected." A former senior NSA official said NSANet "wasn't designed, it evolved" and remains expensive and difficult to replace.

https://breakingthenews.net/Article/NSA-outage-said-to-disrupt-hub-tied-to-Middle-East-operations/67595000

KPMG Canada client files compromised after data breach

 KPMG Canada, the Canadian arm of the accounting giant, is getting in touch with clients whose tax data have been compromised in a recent data breach, The Globe and Mail reported.

The company confirmed the breach took place but didn't reveal the number of affected clients, the number of compromised files, or how the attackers entered the firm's system, the report said.

"We are confident we have protected our clients' information and, based on our ongoing monitoring, the information impacted by this incident is not available online or being misused for any purpose," KPMG spokesperson Sonja Cloutier-Bosworth was cited as having said.

https://breakingthenews.net/Article/KPMG-Canada-client-files-compromised-after-data-breach/67595058

What Is ADHD? Why the ‘Attention Deficit’ Model Falls Short

 Attention-deficit/hyperactivity disorder (ADHD) is a bread-and-butter diagnosis in contemporary psychiatry. Most psychiatrists assess and treat it routinely, and adult diagnoses, in particular, have risen steadily. Yet the working model behind much of this practice rarely goes beyond the diagnostic label: a deficit of attention, a reduced capacity to focus, with or without hyperactivity. 

photo of Awais Aftab, MD
Awais Aftab, MD

The neuropsychological literature has not been kind to that model. Decades of experimental work have produced findings that are inconsistent across tasks, modest in magnitude, and difficult to reconcile with a simple shortfall in attentional capacity. As the evidence has accumulated, it has become less clear that attention is the primary deficit at all, and more plausible that the attentional symptoms clinicians observe are downstream of a different underlying problem. How we answer this question shapes how we assess patients and how we explain the condition to the people who have it.

This article, the first of three, takes stock of the expert consensus on what ADHD is and where leading researchers see that understanding shifting.

Reference Points for Discussion 

Three recent documents are useful anchors for our purposes here.

The World Federation of ADHD International Consensus Statement (2021) distilled 208 conclusions from meta-analyses and large registry studies. It concludes that ADHD, diagnosed by a clinician, is supported by validators and is a clinically useful category in all age groups. It is highly heritable (based on twin studies) and responds well to treatment. However, neither neuropsychological tests nor neuroimaging can diagnose ADHD, and diagnosis rests on clinical assessment.

The 2023 Annual Research Review by Sonuga-Barke and colleagues takes a different tack. It argues that the taxonic model of ADHD as a singular, categorical, neurodevelopmental entity caused by dysfunction within the individual has been strained by accumulated evidence.

Most recently, the October 2025 World Psychiatry Forum brought together international experts with multiple invited commentaries. The review affirms the descriptive, predictive, and concurrent validity of adult ADHD. It also identifies live controversies, such as ADHD with late onset, emotional dysregulation as a core feature, the role of executive dysfunction, objective diagnostic measures, long-term treatment effects, and the place of nonpharmacologic treatment.

These documents by and large defend the utility of the diagnosis while acknowledging that our model of what ADHD refers to is incomplete.

‘Deficit’ to ‘Dysregulation’: What Is Attention’? 

“Attention” means different things in the clinic and in the cognitive neuroscience laboratory. In the lab, it usually means selective amplification of relevant information, such as shifting processing resources to a location in space, or following one conversation in a crowded room. These capacities are tied to the dorsal and ventral attention networks and the frontoparietal network. The classic “inattention” of ADHD criteria is something else: not staying on task, being sidetracked, forgetting instructions, avoiding effortful tasks. As neuroscientist Michael Halassa has noted, these are problems of sustained engagement, not selective processing.

The World Psychiatry review makes a related point. Motivation and task relevance shape symptom expression, and “hyperfocus” in highly rewarding activities is common, so ADHD “can thus be viewed as an attention dysregulation (rather than deficit) disorder.” Many patients can concentrate. What they cannot do is deploy concentration on demand, at the ordinary moments when it is needed.

Researchers, such as Sonuga-Barke, have argued that the behaviors included in the ADHD diagnosis can arise by several distinct routes, such as problems in behavioral inhibition, delay aversion, and disruptions in temporal tracking. Neuropsychological heterogeneity is now the consensus view. Executive dysfunction is present at the group level, but group differences on neuropsychological tests are much smaller than differences in symptoms, and many individuals show no deficits. Coghill notes that fewer than half of people with ADHD perform poorly on formal executive function tests. Rating-scale measures of everyday executive difficulty, such as the BRIEF, correlate strongly with ADHD symptoms but weakly with executive function tests. In other words, “executive function” measured in daily life and in the laboratory are not the same construct. That is the same gap we see with “attention.”

This bears on a live question: Should executive function be a core feature of ADHD? Executive manifestations, such as trouble prioritizing and finishing tasks on time, are among the strongest predictors of an adult diagnosis. Coghill nevertheless argues that executive difficulties are better treated as an associated feature than a core one. Laboratory tasks are brief, novel, and supervised, which are exactly the conditions under which ADHD symptoms tend to normalize and is why neuropsychological research on executive functioning in laboratory settings produces mixed results.

Dimensional, Fluctuating, Broader Phenotype 

Twin heritability of ADHD is about 74% and does not increase with severity, which implies that ADHD is the extreme end of a continuous trait. Taxometric research supports dimensions over categories, and there is no discrete impairment threshold. The World Psychiatry authors state plainly that any clinical cutoff involves a degree of arbitrariness.

ADHD is not the static condition once assumed. In the Multimodal Treatment Study of ADHD, about 60% of remitters experienced recurrence after an initial remission. Symptoms wax and wane with environmental demands. Most children with ADHD no longer meet full criteria by age 30, yet about 70% still have symptoms and about 65% have functional impairment. Adult prevalence is about 2.5%, declining to roughly 1% by age 60.

In the broader phenotype, several features sit at the edge of the current construct:

  • Emotion dysregulation affects close to half of individuals with ADHD. It was central to the earliest descriptions of adult ADHD. Its interpretation is contested. It may be a core feature, a legacy of unrecognized childhood oppositional defiant disorder, or, in some presentations, part of a bipolar spectrum. Brief anger outbursts with rapid return to baseline are read differently by different clinicians. Reif notes that ADHD with depression often shows features of mood disorder and a higher risk for treatment-resistant depression.
  • Cognitive disengagement syndrome, formerly called “sluggish cognitive tempo,” involves daydreaming, mental fogginess, and slowness. A 2023 work group adopted the new name, and it is increasingly seen as a transdiagnostic specifier.
  • Sleep and circadian disturbance are pervasive. Kooij reports that sleep loss affects about 80% of children and adults with ADHD before any stimulant exposure. Delayed sleep phase is the most common comorbid sleep disorder, and evening melatonin onset is delayed by about 1.5 hours in adults with ADHD.
  • Impulsivity is undermeasured. The DSM-5 has only three impulsivity items, while multidimensional measures show adults with ADHD are elevated on negative and positive urgency, lack of premeditation, and lack of perseverance. The apparent decline of impulsivity with age may partly be a measurement artifact.

Rethinking the Construct 

Expert consensus has established that a DSM diagnosis of ADHD is supported by validators, associated with impairment, and treatable in children and adults, but it is neither a discrete disease entity nor explained by central neuropsychological or neurobiological abnormalities. The scientific frontier suggests our model of what it is still needs revision. ADHD looks less like a neuropsychological deficit of attention and more like a heterogeneous, dimensional, fluctuating dysregulation of focus. The problem is not simply an inability to attend. It extends across a range of domains, such as difficulty deploying and sustaining attention and effort when tasks hold little intrinsic value, intertwined with problems of behavioral control, motivation, and arousal. Clinicians should also expect presentations to vary considerably from one patient to the next, and within the same patient over time.

The author used generative AI assistance (Anthropic Claude Opus 5.5) during the writing process. While the core arguments, analysis, and substantive points were entirely conceived and drafted by the author, the AI was utilized to organize detailed bullet points and partial drafts into continuous prose. The final manuscript was thoroughly reviewed, revised, and edited by the author, who takes full responsibility for its content, wording, and accuracy.

Awais Aftab, MD, is a clinical associate professor of psychiatry at Case Western Reserve University in Cleveland, Ohio. His work focuses on conceptual and critical issues in psychiatry, psychopharmacology, and psychiatric diagnosis. He is the author of Conversations in Critical Psychiatry (Oxford University Press, 2024) and writes the Substack newsletter Psychiatry at the Margins. His research and commentary have appeared in leading psychiatric journals and publications, including JAMA Psychiatry, The American Journal of Psychiatry, World Psychiatry, and The New York Times.

https://www.medscape.com/viewarticle/what-adhd-why-attention-deficit-model-falls-short-2026a10017ik

Know Your Parainfluenza (Croup) Phenotypes to Target Care

 All parainfluenza viruses (PIVs) are not equal, and better identification of the type of PIV in a sick child can inform diagnosis, risk stratification, and patient care, according to a new state-of-the-science review published in Pediatrics.

“Parainfluenza viruses are an important cause of pediatric respiratory disease, yet they are often viewed primarily as pathogens causing croup,” said corresponding author Andrea Jaramillo-Cerezo, MD, a pediatrician at the Universidad Pontificia Bolivariana, Medellin, Colombia. The review highlights the distinct epidemiologic and clinical profiles of the four types of PIV, with important differences in age distribution, respiratory involvement, and disease severity, she said.

A notable clinical difference is the relatively short (51 days) biological half-life of maternally derived PIV-3 antibodies which means about 50% of children are infected before 1 year of age, whereas infection with PIV-1 and PIV-2 tends to occur at toddler and preschool ages. Although the reason for this difference remains unclear, it is consistent with the pattern of croup in older children caused by PIV-1 and PIV-2, with PIV-3 causing bronchiolitis and pneumonia in infants. Approximately 50% of children are infected before 1 year of age, the authors said.

“I was particularly struck by the clinical relevance of PIV-4, which has historically been underrecognized because of limitations in conventional diagnostic methods,” said Jaramillo-Cerezo. “Molecular testing has revealed its association with lower respiratory tract disease, hypoxemia, and, in some cases, neurologic complications; this reinforces how improved diagnostics can change our understanding of a pathogen’s clinical impact,” she noted.

PIV-1 remains the most common cause of laryngotracheobronchitis (croup) in children, with a peak age of 2 years, the authors noted. Approximately half of primary PIV-1 infections are subclinical. Symptoms are usually mild and resolve within 48 hours in approximately two thirds of cases. However, bacterial tracheitis can arise as a secondary infection, and should be suspected in patients who fail to respond to epinephrine, especially those with a high fever and tracheal secretions.

PIV-2 also contributes to the croup burden, and although it is often associated with milder illness, data from a previous study showed the highest rates of ICU admission and intubation for PIV-2 across all four types. Hospitalization for PIV-2 infection is more likely in children with underlying neurologic or neuromuscular conditions, the authors wrote. PIV-2 infections are often associated with higher and more frequent fevers and more frequent elevated C-reactive protein measures than other infection types.

PIV-3 hits harder in young infants and accounts for more than half of all PIV cases detected. Approximately 50% of children are infected before 1 year of age, and up to 92% by 4 years of age, as noted in Clinical Microbiology Reviews. Early postnatal susceptibility, which may relate to earlier and more frequent viral exposure, may play a role, the authors said.

PIV-4 has been underrecognized because of diagnostic limitations and was previously considered mild. However, new molecular methods have incriminated PIV-4 in more cases of pneumonia and lower respiratory tract infections than the other three types, a comparative study in The Journal of Infectious Diseases showed.

Trends, Technology, and Treatment

Overall, PIV infections are most severe in infants, immunocompromised children, and those in low-resource settings. Seasonal patterns vary by type and geography. PIV-1 generally drives biennial autumn epidemics, alternating with PIV-2. PIV-3 tends to peak in spring and summer, whereas PIV-4 circulates in autumn and winter.

No vaccine or antiviral is currently licensed for pediatric PIV, and the need for protection against four distinct types poses an additional challenge, the authors said. However, researchers are exploring multiple avenues.

Despite not meeting the primary endpoint, a recombinant sialidase known as DAS-181 (Fludase) is in a phase 3 clinical trial, with FDA Breakthrough Therapy and Fast Track designations. In addition, researchers are building on the success of prefusion F stabilization in RSV vaccines to explore prefusion F for PIV, and several monoclonal antibody candidates are in preclinical development (PIV3-23, PIV3-18, PI3-E12).

Avoid considering PIV a single clinical entity, or simply the virus responsible for croup, said Jaramillo-Cerezo. “Clinicians should interpret type-specific molecular results in the context of the patient’s age and clinical presentation, particularly in young infants and immunocompromised children. Although treatment remains mainly supportive, recognizing these differences can improve clinical assessment and risk stratification,” she said.

Jaramillo-Cerezo noted the heterogeneity of the available literature, including differences in populations, diagnostic methods, and clinical outcomes limited this review. In addition, type-specific epidemiologic data remain limited in several regions, particularly Latin America, she said. “Prospective multicenter studies and stronger surveillance systems are needed to better characterize disease burden, clinical outcomes, and regional circulation patterns, alongside continued evaluation of emerging vaccines and therapeutics,” Jaramillo-Cerezo said.

View From the Clinic

“Each PIV type exhibits unique clinical, epidemiologic, and virologic characteristics that can influence diagnosis, management, and preventive strategies,” said Shirin Mazumder, MD, an infectious diseases specialist and associate professor at The University of Tennessee Health Sciences in Memphis.

Diagnosing the different PIV phenotypes can be challenging in the clinical setting, said Mazumder, who was not involved in the review. Conventional methods such as traditional cell culture and direct fluorescent antibody tests often fail to detect certain PIV types, she noted.

Advancements in molecular diagnostics shorten the testing turnaround time and increase the sensitivity of detecting all four PIV types, which helps to support treatment decisions, said Mazumder.

Improvements in diagnosis and targeted treatment of hospitalized or high-risk patients could reduce progression from upper to lower respiratory disease and reduce ICU admission and mortality rates and reduce reliance on empiric antibiotics, Mazumder said. Effective mRNA vaccines could be integrated into childhood immunization schedules, dramatically reducing the incidence of severe disease, hospitalizations, and PIV-related deaths globally, and early vaccination could help to close the susceptibility gap in infants, especially for PIV-3, where maternal antibodies wane more rapidly, she said.

Further clarification of the distinct epidemiology, severity, and complications of each PIV type would improve patient management, said Mazumder. “Given that the highest burden of severe disease and mortality occurs in low-resource regions, implementation studies are needed to ensure that future preventive, diagnostic, and therapeutic advances reach the populations most at risk,” she said.

The study received no outside funding. The researchers had no financial conflicts to disclose. Mazumder had no financial conflicts to disclose.

https://www.medscape.com/viewarticle/know-your-parainfluenza-phenotypes-target-care-2026a10018x8

The Fake 96,000-Patient Database That Sank Hydroxychloroquine... And Medicine's Growing Black-Box

 by Maryanne Demasi via Brownstone Institute,

On May 22, 2020, the Lancet published a study that changed the course of the Covid-19 pandemic.

It purported to analyze the medical records of 96,032 patients hospitalized with Covid-19 across 671 hospitals and six continents, delivering a damning conclusion about an old antimalarial drug - hydroxychloroquine.

Patients treated with hydroxychloroquine alone or with a macrolide antibiotic appeared more likely to develop dangerous heart rhythm disturbances and more likely to die.

The study's findings dealt a major blow to hydroxychloroquine - a cheap, off-patent drug that was already at the center of a fierce political battle.

President Donald Trump had publicly championed hydroxychloroquine as a potential Covid treatment and called for research to be accelerated - even revealing that he was taking the drug himself.

Within days of the study appearing in the Lancet, the World Health Organization suspended the hydroxychloroquine arm of its multinational Solidarity trial. Other trials were interrupted, and treatment policies changed around the world.

The study carried enormous authority because of its size. Nearly 100,000 patient records appeared to provide the kind of real-world evidence clinicians desperately wanted while conventional randomized trials were still underway.

But there was a problem - investigators quickly concluded the database was fake.

The company behind it was Surgisphere, an obscure Chicago operation. What followed was one of the most extraordinary scientific collapses in modern history, exposing how easily global health policy could be swayed by unverified data.

Six years later, Surgisphere is worth revisiting - not as a one-off pandemic anomaly, but because the weakness it revealed in modern healthcare data has only become more consequential.

The Sleuths

Among those scrutinizing the Lancet paper was physician James Todaro, who had been closely following the emerging hydroxychloroquine literature.

Todaro wasn't surprised that hydroxychloroquine showed little benefit in severely ill patients. What caught his attention was the substantially higher mortality - an extraordinary safety signal for a cheap, decades-old drug with a well-established safety profile.

Clinicians, statisticians, epidemiologists, and independent researchers began pulling apart the paper.

One of the first major discrepancies came from Australia. The study claimed to include 600 Australian patients from five hospitals, with 73 deaths recorded by April 21, 2020. But only 67 Covid deaths had been recorded in the entire country by that date.

Something wasn't adding up. The data contained more Australian deaths than Australia itself had recorded.

The Guardian contacted hospitals in Melbourne and Sydney whose participation would have been necessary to reach the numbers reported in the paper. All denied contributing to the database and said they had never heard of Surgisphere.

The company said one Asian hospital had accidentally been assigned to Australia. The figures were corrected, and the authors maintained that the mistake did not alter the conclusions.

But researchers kept looking.

The study also claimed to contain detailed clinical data from hospitals across Africa, including information derived from continuous cardiac monitoring.

Collecting and transmitting that level of granular, near-real-time information requires expensive and sophisticated electronic hospital infrastructure - technology that many African hospitals simply did not have.

Researchers questioned how Surgisphere could possibly have obtained such comprehensive electronic records from facilities where the systems needed to generate them were unlikely to exist.

Then there was North America. The study claimed to have records for approximately 63,000 hospitalized Covid patients from the region - roughly equivalent to the total number of Covid hospitalizations reported across the entire United States at the time.

If the numbers were genuine, Surgisphere had somehow captured detailed clinical records for virtually every hospitalized Covid patient in America, across hundreds of independent hospitals using different electronic medical-record systems.

It was an extraordinary claim. If true, Surgisphere had accomplished something that major health systems and technology companies had struggled to achieve for years: connecting hundreds of hospitals using different electronic medical-record systems and extracting detailed, standardized clinical information on tens of thousands of patients across multiple countries, almost in real time.

Todaro later described a database with that capability as the "holy grail" of medical research. The idea that an obscure company had quietly built it without anyone in the field knowing about it was increasingly difficult to believe.

The Company Behind the Data

A global healthcare database spanning hundreds of hospitals would require substantial technical infrastructure - software engineers, database architects, statisticians, data-security specialists, and clinical informatics teams.

But investigators found nothing resembling such an operation.

Surgisphere's website was heavy with references to artificial intelligence, machine learning, and advanced analytics, but provided little evidence of how its vast international data network actually operated.

Its public footprint showed only a handful of employees and no visible army of data engineers capable of building and maintaining the system described in the papers.

The company's founder and lead author, Sapan Desai, was a vascular surgeon who had also written science-fiction novels.

Media investigations uncovered even stranger details about the small group of people associated with the company. The Guardian revealed that one employee, listed as a marketing executive, was an adult model and events hostess.

As researchers and journalists dug deeper, pages disappeared from Surgisphere's website, and claims about academic relationships were altered or removed.

The company had supposedly built a research asset of extraordinary value - a database spanning hundreds of hospitals and tens of thousands of patients that would ordinarily generate years of publications across numerous diseases.

If only it were true.

Who Had Actually Checked the Data?

The Lancet paper contained an important declaration: all four authors stated that they had full access to the data and accepted responsibility for its integrity.

But that assurance soon unraveled.

On June 2, 2020, more than 200 scientists, clinicians, and statisticians signed an open letter detailing serious concerns about the study's methods and data, and demanding independent validation.

An audit could have resolved the dispute.

But when asked to provide the data, the study's lead author, Harvard cardiologist Professor Mandeep Mehra, reportedly replied: "Our data sharing agreements with the various governments, countries and hospitals do not allow us to share data unfortunately."

Three of the four authors then said they could no longer vouch for the primary data because they had been unable to complete an independent review.

By June 4, 2020, it was all over. The authors abandoned the study, and the Lancet retracted it. On the same day, the New England Journal of Medicine retracted another Covid study built on the same database.

A Failure Beyond Surgisphere

The scandal was widely treated as an extraordinary case of scientific fraud during a chaotic time, but its true significance lies in what it exposed.

Neither the peer-reviewers nor the journal editors had verified the underlying data, and outside researchers were barred from inspecting it. None of that stopped the study from rewriting global health policy overnight.

Recognizing the failure, the Lancet published a statement in September 2020 titled "Learning from a retraction," introducing new safeguards for research reliant on large datasets.

The journal mandated that multiple authors directly access and verify raw data, required data-sharing statements, and introduced specialized data-science peer review.

These reforms were a clear admission of systemic failure, but they left a critical flaw unresolved.

Requiring authors to verify the dataset delivered to them is not the same as requiring them - or independent researchers - to verify those data against the original source medical records.

Six years later, that distinction has become critical. Modern medicine is embracing real-world evidence at an unprecedented scale, relying on massive aggregations of electronic health records, insurance claims, and disease registries to evaluate major drugs and vaccines.

Massive datasets containing the health records of millions of patients now underpin thousands of studies on drug safety, vaccines, and treatment effectiveness.

Regulators are increasingly relying on them too.

Last December, then-FDA Commissioner Marty Makary announced plans to expand the agency's use of "real-world evidence" in regulatory decisions.

"We're removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster," Makary said.

There are valid reasons for the shift. Electronic health records covering millions of patients can reveal rare side effects and long-term outcomes that clinical trials may be too small or too short to detect.

But there is a problem. Much of this research relies on enormous, heavily processed datasets that researchers and independent reviewers cannot readily check against the original hospital records.

The danger became clear during the Surgisphere scandal in 2020, when the database underpinning a major Covid-19 study that influenced health policy turned out to be fake.

Six years later, the same fundamental problem remains.

If neither researchers nor independent reviewers can trace the data back to the original medical records, how do we know they are reliable?

Who Controls the Data?

Patient records are scattered across thousands of hospitals, stored in different computer systems, and protected by strict privacy laws.

Before researchers can analyze them, those records must be extracted, stripped of identifying information, converted into standardized codes, and assembled into research-ready databases.

The use of these datasets has exploded. A PubMed search for "real world evidence" or "real world data" shows how rapidly the field has grown over the past two decades (see graph).

Between the original medical record and the scientist who eventually analyzes it sits something of a black box.

This has created a powerful role for middlemen - companies and research networks that extract, process, and package medical records into datasets for researchers to analyze.

Commercial data companies, such as IQVIA, TriNetX and Merative, along with research networks such as OHDSI and PEDSnet, now occupy this space.

They largely draw on real patient data from electronic health records, Medicare, insurance claims, and other healthcare databases.

But some, such as OHDSI, can also work with synthetic data - artificially generated patient records that mimic the characteristics of real healthcare data but do not represent actual patients.

By the time researchers receive the data, the records may already have passed through multiple stages of extraction, coding, filtering and software transformation.

Several organizations involved in this process also have financial ties to the pharmaceutical industry.

TriNetX, for example, received venture backing from Merck's Global Health Innovation Fund. OHDSI was launched by Janssen, and receives financial support from pharmaceutical companies including Takeda, Janssen, AstraZeneca, Merck and Pfizer.

Those relationships do not mean the databases are inherently corrupted or biased, but when organizations involved in processing the data also have commercial interests, independent scrutiny of how the data are handled becomes even more important.

The Secrecy of PEDSnet

PEDSnet provides a window into how this data pipeline works.

This large US research network turns electronic health records from major children's hospitals into datasets for medical research. During the pandemic, it was used for influential studies examining the safety and effectiveness of Covid-19 vaccines in children.

In 2024, researchers published a study using PEDSnet data to evaluate Pfizer's Covid vaccine in adolescents. The result was striking.

The authors reported 98.4% effectiveness against documented infection in adolescents during the Delta wave, with no statistically significant waning after the first dose - effectively claiming near-perfect protection.

Another high-profile PEDSnet study later reported that Pfizer's vaccine was 95.4% effective against long Covid in adolescents during the Delta period, based on records from 20 US health systems.

To some researchers, those extraordinary figures seemed "highly implausible," prompting them to look more closely at the underlying data. But when they tried to re-examine them, they hit a wall.

The paper stated that the data were "not publicly available due to privacy concerns," adding that they "may be available through submitting PEDSnet Study Approval applications."

In a public exchange on X, one of the study's senior authors, biostatistician Professor Jeffrey Morris, stated, "I don't know and don't have access to those data."

Morris later explained that access was governed by strict consortium protocols.

"The PEDSNet data is a consortium repository of complete medical records for millions of children so...they are not 'public' by law," he said, adding that his colleagues "are not at liberty to share the data."

One of the papers, however, stated that eight authors had "accessed and verified the data." Corresponding author Christopher Forrest was among them.

MD Reports contacted the authors, including Forrest, asking about data access, but there was no response. PEDSnet also did not respond.

It therefore remains unclear what was actually verified - and whether anyone checked the research dataset against the original hospital records.

So when scientists say they have "verified" a dataset, what exactly have they verified?

Who Gets to See the Underlying Data?

A 2021 report prepared for the US Department of Health and Human Services provides a rare look inside these research networks.

It examined 15 major networks, including PEDSnet, PCORnet, FDA Sentinel, and OHDSI.

Access to patient-level information is tightly controlled. The report noted that "only authorized individuals at each data provider organization have access to patient-level information."

Outside researchers can submit instructions specifying what they want analyzed. Depending on the network and project, they may receive deidentified or aggregated results - sometimes only summaries - rather than the underlying medical records.

These restrictions are intended to protect patient privacy. But deidentifying, summarizing, enhancing, and imputing data requires additional processing, and each step creates another opportunity for errors or distortions to creep in.

The HHS report itself warned that automated quality checks cannot catch every error. Data that pass validation can later be "found erroneous in unexpected ways, even in environments with long-established data workflows."

That goes to the heart of the problem.

Researchers are often unable to check whether the data they receive faithfully reflect what was originally recorded at the hospital. If an error was introduced before the dataset reached them, it may simply pass through unnoticed.

That is precisely what Surgisphere exposed - researchers analyzed a database they believed contained genuine hospital records, without being able to verify those records at their source.

Compounding the problem, independent researchers trying to scrutinize or replicate published findings often struggle to obtain the dataset at all.

The result is a black box at both ends - researchers cannot verify the data against the original medical records, and outsiders cannot independently check the data after publication.

When Researchers Get to Check

A recent dispute over HPV vaccination in Scotland shows what can happen when researchers are given access to the underlying data.

The original Scottish study used national health registry records and made international headlines after reporting "zero cases" of invasive cervical cancer among women vaccinated against HPV at ages 12 or 13.

Two Australian researchers, Associate Professors Samir Saidi and Mark Jones, requested the underlying dataset from the Scottish researchers.

They received it in full, deidentified and without financial cost or legal restrictions.

When Saidi and Jones reanalyzed the anonymized data, the picture changed dramatically.

They found key differences between the vaccinated and unvaccinated groups, questioned the population figures used in the analysis, and argued that the celebrated "zero cancer" finding was largely explained by the women's young age and short follow-up.

The merits of the statistical debate aside, the important point is that the data could be checked. There was no black box, and without access, the problems Saidi and Jones identified would probably never have surfaced.

The Reproducibility Problem

That kind of scrutiny is fundamental to science. Important findings should be open to independent checking and replication.

NIH Director Jay Bhattacharya has made replication and reproducibility a major agency-wide priority.

The NIH describes replication and reproducibility as "foundational to the conduct of gold standard science," with its new initiative focused on data sharing, standardization, and independent replication.

That push now extends to the provenance of real-world data. The NIH's new Data COUNTS initiative aims to preserve the "full data provenance and lineage" of electronic health records - allowing researchers to trace where the data came from and what happened to them along the way.

Longstanding NIH publishing principles state that, where ethically appropriate, "all datasets on which the conclusions of the paper rely must be made available" to reviewers during peer review and upon reasonable request after publication.

In practice, researchers seeking access to data can face lengthy application processes, outright refusals, or fees that make independent scrutiny difficult or impossible.

Patient privacy is essential, but it need not preclude independent scrutiny.

Researchers can be given controlled access through secure systems, while independent audits can verify whether research datasets accurately reflect the original records without exposing patients' identities.

At the very least, there should be a clear audit trail showing how the original records were turned into the dataset used in the study.

Medicine's New Black Box

The problem exists at both ends.

Before researchers see the data, patient records have already been extracted, enhanced, coded, and transformed. After publication, independent researchers may be unable to obtain the dataset to check the findings for themselves.

Between the two sits an increasingly powerful layer of commercial data companies and research networks controlling how medical information is processed and who gets to see it.

Surgisphere was not simply an isolated pandemic scandal. It exposed a weakness in a research system increasingly dependent on enormous datasets that few people evaluating the resulting science will ever see.

Six years later, the datasets are vastly larger, the software more complex, and their influence over healthcare greater than ever.

The NIH now says research data should have traceable "provenance and lineage." That standard should extend through the entire research chain.

Researchers must be able to examine the underlying data themselves, or there must be an independent way to verify where the data came from and how they were processed.

Otherwise, "accessed and verified" risks becoming little more than a box to tick, while medicine is still being asked to trust the black box.

https://www.zerohedge.com/medical/fake-96000-patient-database-sank-hydroxychloroquine-and-medicines-growing-black-box